- Home
- ELEV vs CRIS Comparison
ELEV vs CRIS Comparison
Compare ELEV & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- CRIS
- Stock Information
- Founded
- ELEV 2019
- CRIS 2000
- Country
- ELEV United States
- CRIS United States
- Employees
- ELEV N/A
- CRIS N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELEV Health Care
- CRIS Health Care
- Exchange
- ELEV Nasdaq
- CRIS Nasdaq
- Market Cap
- ELEV 37.6M
- CRIS 32.8M
- IPO Year
- ELEV 2021
- CRIS 2000
- Fundamental
- Price
- ELEV $0.61
- CRIS $3.10
- Analyst Decision
- ELEV Buy
- CRIS Strong Buy
- Analyst Count
- ELEV 6
- CRIS 3
- Target Price
- ELEV $7.20
- CRIS $23.00
- AVG Volume (30 Days)
- ELEV 1.3M
- CRIS 29.3K
- Earning Date
- ELEV 03-05-2025
- CRIS 03-04-2025
- Dividend Yield
- ELEV N/A
- CRIS N/A
- EPS Growth
- ELEV N/A
- CRIS N/A
- EPS
- ELEV N/A
- CRIS N/A
- Revenue
- ELEV N/A
- CRIS $10,259,000.00
- Revenue This Year
- ELEV N/A
- CRIS N/A
- Revenue Next Year
- ELEV N/A
- CRIS N/A
- P/E Ratio
- ELEV N/A
- CRIS N/A
- Revenue Growth
- ELEV N/A
- CRIS 0.44
- 52 Week Low
- ELEV $0.50
- CRIS $2.86
- 52 Week High
- ELEV $5.83
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- ELEV 43.44
- CRIS 41.55
- Support Level
- ELEV $0.64
- CRIS $3.10
- Resistance Level
- ELEV $0.72
- CRIS $3.32
- Average True Range (ATR)
- ELEV 0.05
- CRIS 0.18
- MACD
- ELEV -0.00
- CRIS -0.01
- Stochastic Oscillator
- ELEV 18.41
- CRIS 9.62
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.